Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 18/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485450 | 0.86 | BTN3A1 (0.68) | BTN3A1 | |
| SCHEMBL24835115 | 0.83 | BTN3A1 (1.00) | BTN3A1 | |
| SCHEMBL12640204 | 0.83 | BTN3A1 (1.00) | BTN3A1 | |
| SCHEMBL10002547 | 0.83 | BTN3A1 (1.00) | BTN3A1 | |
| SCHEMBL20411334 | 0.78 | BTN3A1 (0.69) | BTN3A1 | |
| SCHEMBL18382997 | 0.76 | BTN3A1 (0.71) | BTN3A1 | |
| SCHEMBL12640203 | 0.76 | BTN3A1 (1.00) | BTN3A1 | |
| SCHEMBL13101858 | 0.75 | BTN3A1 (1.00) | BTN3A1 | |
| SCHEMBL12640196 | 0.75 | BTN3A1 (1.00) | BTN3A1 | |
| SCHEMBL18383186 | 0.73 | BTN3A1 (0.65) | BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | INNATE PHARMA, S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| WO-2008059052-A1 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007057440-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029674-A1 | Methods of Using Phosphoantigen for the Treatment of Cancer | CD4, CD74, TP53 | BTN3A1 536/4885 |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | BTN3A1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.